Incyte Corporation vs Nebius Group NV — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Nebius Group NV trades at $219.11 (market cap $46.37B). The key difference: Nebius Group NV is far larger — about 2× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Nebius Group NV nearer its low. Which is the better fit depends on your goals.
| INCY | NBIS | |
|---|---|---|
Market Cap | $23.11B | $46.37B |
Sector | Health | Technology |
52-Week High | $118.52 | $286.69 |
52-Week Low | $67.38 | $50.40 |
Enterprise Value | $19.13B | $46.56B |
Trailing returns across standard periods
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →